Register to submit your paper, and Start Earning from your Research Articles
Share Your Oncology Research — Publish and Earn
In the rapidly evolving world of cancer research and oncology, timely knowledge sharing can make a real difference in patient outcomes and therapeutic development. Whether you're studying tumor biology, clinical oncology, or cutting-edge immunotherapy techniques, our multidisciplinary publishing platform provides an open space for your discoveries — with monetization opportunities built-in.
Why Publish Oncology Articles with Us?
Traditional peer review can delay the visibility of important oncology findings. Our non-peer-reviewed model allows you to share impactful cancer research directly and rapidly with fellow researchers, medical professionals, and healthcare innovators worldwide. From lab studies to clinical observations, your work can reach the audience it deserves.
From Benchside Discovery to Bedside Impact
Cancer research drives breakthroughs in early detection, treatment protocols, and patient care. Whether your focus is on genomics, targeted therapies, or epidemiological cancer trends, our platform invites contributions from all corners of the oncology community. Your work can inform real-world decisions and fuel future research directions.
Monetize Your Expertise
Publishing isn't only about academic recognition; it's also about earning value for your efforts. Our platform gives oncology researchers the option to monetize their content while contributing to the global cancer research conversation. If you're seeking an alternative to conventional medical journals, this is your invitation to submit.
Join a growing network of oncologists, cancer research specialists, and medical writers. Submit your oncology articles today and turn your insights into both impact and income.
Sophie FERLICOT,
Sophie FERLICOT
Institution: Université Paris-Saclay Faculté de Médecine: Universite Paris-Saclay Faculte de Medecine
Email:
Pierre-Alexandre Just,
Pierre-Alexandre Just
Institution: APHP: Assistance Publique - Hopitaux de Paris
Email:
Eva Compérat,
Eva Compérat
Institution: APHP: Assistance Publique - Hopitaux de Paris
Email:
Etienne Rouleau,
Etienne Rouleau
Institution: Gustave Roussy Institute: Gustave Roussy
Email:
Frédérique Tissier,
Frédérique Tissier
Institution: APHP: Assistance Publique - Hopitaux de Paris
Email:
Christophe Vaessen,
Christophe Vaessen
Institution: APHP: Assistance Publique - Hopitaux de Paris
Email:
Stéphane Richard
Stéphane Richard
Institution: EPHE: Ecole Pratique des Hautes Etudes
Email:
Background: Hereditary papillary renal cell carcinoma (HPRCC) is a rare autosomal dominant disease characterized by the development of multiple and bilateral papillary type I renal cell carcinomas (RCC) and papillary adenomas caused by activating mutations in the MET proto-oncogene. Classically, distinctive histological features of RCC are described according to the familial renal cell carcinoma s...
6 months ago
Ichiro Tsuboi,
Ichiro Tsuboi
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Momoko Araki,
Momoko Araki
Institution: Shimane University Faculty of Medicine Department of Clinical Genetics Unit, , Izumo, Japan
Email:
Shuhei Yokoyama,
Shuhei Yokoyama
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Gen Tanaka,
Gen Tanaka
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Kazutaka Mitani,
Kazutaka Mitani
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Saori Yosioka,
Saori Yosioka
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Yusuke Kobayashi,
Yusuke Kobayashi
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Hirochika Nakajima,
Hirochika Nakajima
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Taichi Nagami,
Taichi Nagami
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Kohei Ogawa,
Kohei Ogawa
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Chiaki Koike,
Chiaki Koike
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Koichiro Wada
Koichiro Wada
Institution: Shimane University Faculty of Medicine Department of Urology, , Izumo, Japan
Email:
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal-dominant disorder caused by a heterozygous germline mutation in the fumarate hydratase (FH) gene. HLRCC is clinically characterized by the development of three tumors: uterine leiomyomata, cutaneous leiomyomata, and renal cell carcinoma (RCC). HLRCC-associated RCC is aggressive and diagnosed at a much earlier age than spor...
6 months ago
Akihiro Ohmoto,
Akihiro Ohmoto
Institution: NULL
Email:
Naomi Hayashi,
Naomi Hayashi
Institution: NULL
Email:
Shunji Takahashi,
Shunji Takahashi
Institution: NULL
Email:
Arisa Ueki
Arisa Ueki
Institution: NULL
Email:
Adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL) are two rare types of adrenal gland malignancies. Regarding hereditary tumors, some patients with ACC are associated with with Li-Fraumeni syndrome (LFS), and those with PPGL with multiple endocrine neoplasia type 2. Recent studies have expanded this spectrum to include other types of hereditary tumors, such as Lynch syndrome...
6 months ago
Annmarie Taheny,
Annmarie Taheny
Institution: NULL
Email:
Haylie McSwaney,
Haylie McSwaney
Institution: NULL
Email:
Julia Meade
Julia Meade
Institution: NULL
Email:
Current National Comprehensive Cancer Network ® (NCCN ®) guidelines for Colorectal Genetic/Familial High-Risk Assessment provide limited guidance for genetic testing for individuals with already diagnosed hereditary cancer conditions. We are presenting the case of a 36-year-old woman who was diagnosed with Lynch Syndrome at age 23 after genetic testing for a familial variant (c.283del) in the ML...
6 months ago
Fangfang Gao,
Fangfang Gao
Institution: NULL
Email:
Dejian Gu,
Dejian Gu
Institution: NULL
Email:
He Zhang,
He Zhang
Institution: NULL
Email:
Chao Shi,
Chao Shi
Institution: NULL
Email:
Feng Du,
Feng Du
Institution: NULL
Email:
Bo Zheng,
Bo Zheng
Institution: NULL
Email:
Huijuan Wu,
Huijuan Wu
Institution: NULL
Email:
Yanqiu Zhao
Yanqiu Zhao
Institution: NULL
Email:
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal dominant syndrome caused by a germline mutation in the fumarate hydratase (FH) gene that manifests with cutaneous leiomyomas, uterine fibroids, and renal cell cancer (RCC). Patients with HLRCC-associated RCC (HLRCC-RCC) have aggressive clinical courses, but there is no standardized therapy for advanced HLRCC-RCC. In this s...
6 months ago
Stuart S Berr,
Stuart S Berr
Institution: NULL
Email:
Antonio Gonzalez
Antonio Gonzalez
Institution: NULL
Email:
Glioblastoma (GB) is the most common brain cancer and has limited survivability with a mean survival time of 15 months and an overall survival of less than 7 % after 5 years. Impediments to delivery of large molecule (e.g. antibodies) and cell therapeutics to a tumor include the blood–brain barrier (BBB) and the blood‐tumor barrier (BTB) which prevent large solutes from crossing from circulati...
7 months ago
Amena Ali Hussain,
Amena Ali Hussain
Institution: NULL
Email:
Eva Forssell-Aronsson,
Eva Forssell-Aronsson
Institution: NULL
Email:
Tobias Rosholm,
Tobias Rosholm
Institution: NULL
Email:
Esmaeil Mehrara
Esmaeil Mehrara
Institution: NULL
Email:
PET/CT and PET/MRI are valuable multimodality imaging techniques for visualizing both functional and anatomical information. The most used PET reconstruction algorithm is Ordered Subset Expectation Maximization (OSEM). In OSEM, the image noise increases with increased number of iterations, and the reconstruction needs to be stopped before complete convergence. The Bayesian penalized likelihood (BP...
7 months ago
Ilaria Proietti,
Ilaria Proietti
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
Chiara Battilotti,
Chiara Battilotti
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
Francesca Svara,
Francesca Svara
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
Ersilia Tolino,
Ersilia Tolino
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
Nicoletta Bernardini,
Nicoletta Bernardini
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
Nevena Skroza,
Nevena Skroza
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
Luca Filippi,
Luca Filippi
Institution: Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy
Email:
Concetta Potenza
Concetta Potenza
Institution: Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
Email:
The use of hyaluronic acid (HA) fillers in oncology patients undergoing PET-CT scans is a topic of debate due to potential interference with imaging accuracy. A 54-year-old female, postmelanoma metastasectomy in the parotid region with subsequent facial nerve palsy (FNP), received HA filler injections for facial symmetry and functional restoration. Follow-up PET-CT scans showed no interference or ...
7 months ago
Effective management of the COVID-19 pandemic requires widespread and frequent testing of the population for SARS-CoV-2 infection. Saliva has emerged as an attractive alternative to nasopharyngeal samples for surveillance testing as it does not require specialized personnel or materials for its collection and can be easily provided by the patient. We have developed a simple, fast, and sens...
8 months ago